These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19555670)

  • 1. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
    Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C
    Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
    Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
    Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
    Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
    Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF signaling inhibits the proliferation of human myeloma cells and reduces c-myc expression.
    Firme L; Bush AB
    BMC Cell Biol; 2003 Dec; 4():17. PubMed ID: 14656381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
    Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
    Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
    Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes.
    Priore R; Dailey L; Basilico C
    J Cell Physiol; 2006 Jun; 207(3):800-8. PubMed ID: 16523491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
    Ferrajoli A; Faderl S; Van Q; Koch P; Harris D; Liu Z; Hazan-Halevy I; Wang Y; Kantarjian HM; Priebe W; Estrov Z
    Cancer Res; 2007 Dec; 67(23):11291-9. PubMed ID: 18056455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of lymphocyte function associated antigen 1 by LFA878 induces apoptosis in multiple myeloma cells and is associated with downregulation of the focal adhesion kinase/phosphatidylinositol 3 kinase/Akt pathway.
    Schmidmaier R; Mandl-Weber S; Gaul L; Baumann P; Bumeder I; Straka C; Emmerich B
    Int J Oncol; 2007 Oct; 31(4):969-76. PubMed ID: 17786331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals.
    Ishikawa H; Tsuyama N; Liu S; Abroun S; Li FJ; Otsuyama K; Zheng X; Ma Z; Maki Y; Iqbal MS; Obata M; Kawano MM
    Oncogene; 2005 Sep; 24(41):6328-32. PubMed ID: 15940250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase-9 pathway activation by inhibiting endogenous fibroblast growth factor signaling in human glioma cells.
    Fukushima S; Kato S; Maeda M; Shigemori M
    Int J Oncol; 2008 Feb; 32(2):467-73. PubMed ID: 18202770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
    Verdelli D; Nobili L; Todoerti K; Intini D; Cosenza M; Civallero M; Bertacchini J; Deliliers GL; Sacchi S; Lombardi L; Neri A
    Hematol Oncol; 2009 Mar; 27(1):23-30. PubMed ID: 18759374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF signaling network in the gastrointestinal tract (review).
    Katoh M; Katoh M
    Int J Oncol; 2006 Jul; 29(1):163-8. PubMed ID: 16773196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
    Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
    Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis.
    Li QF; Wu CT; Duan HF; Sun HY; Wang H; Lu ZZ; Zhang QW; Liu HJ; Wang LS
    Br J Haematol; 2007 Sep; 138(5):632-9. PubMed ID: 17686057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.